Shire’s board last night set the stage for a potential Takeda acquisition by saying it would recommend to shareholders approval of Takeda’s approximately £46 billion ($64 billion) offer for the company—if other terms can be worked out.
London-listed drugmaker Shire Plc and Japan's Takeda Pharmaceutical Co Ltd plan to announce a preliminary deal on Wednesday, after the latter sweetened its US$62 billion acquisition offer, people familiar with the matter said.
Takeda, with apparently near infinitely deep pockets for M&A and collaborations, has struck a deal: not to buy Shire, as yet, but rather with Nektar, as the two eye new trials of their respective immuno-oncology assets.
Oops! Unable to complete your request. Please refresh your browser.